-
公开(公告)号:US20220356167A1
公开(公告)日:2022-11-10
申请号:US17197399
申请日:2021-03-10
发明人: Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC分类号: C07D401/14 , C07D417/14 , C07D413/14 , C07D403/12 , C07D403/14 , C07D405/14
摘要: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号:US11345699B2
公开(公告)日:2022-05-31
申请号:US16688429
申请日:2019-11-19
发明人: Brett Granger , Guoqiang Wang , Ruichao Shen , Jing He , Yong He , Xuechao Xing , Jun Ma , Jiang Long , Bin Wang , Yat Sun Or
IPC分类号: C07D471/04 , C07D401/14 , C07D417/14 , C07D405/14 , C07D413/14
摘要: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
3.
公开(公告)号:US20220119366A1
公开(公告)日:2022-04-21
申请号:US17228815
申请日:2021-04-13
发明人: Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC分类号: C07D401/14 , C07D413/14 , C07D405/14 , C07D409/14 , C07D417/14
摘要: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
-
公开(公告)号:US10988458B2
公开(公告)日:2021-04-27
申请号:US16866778
申请日:2020-05-05
发明人: Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC分类号: C07D401/14 , C07D405/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D403/12
摘要: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号:US10696713B2
公开(公告)日:2020-06-30
申请号:US16222380
申请日:2018-12-17
发明人: Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
摘要: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号:US10246439B2
公开(公告)日:2019-04-02
申请号:US15988783
申请日:2018-05-24
发明人: Brett Granger , Guoqiang Wang , Ruichao Shen , Jun Ma , Xuechao Xing , Jing He , Yong He , Jiang Long , Bin Wang , Yat Sun Or
IPC分类号: C07D401/14 , C07D487/08 , C07D491/08 , C07D513/04 , C07D417/14
摘要: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
7.
公开(公告)号:US20190062310A1
公开(公告)日:2019-02-28
申请号:US16113611
申请日:2018-08-27
发明人: Guoqiang Wang , Jing He , Bin Wang , Ruichao Shen , Brett Granger , Yat Sun Or
IPC分类号: C07D401/14 , C07D413/14 , C07D471/04
CPC分类号: C07D401/14 , A61P1/16 , A61P3/10 , A61P13/12 , C07D413/14 , C07D471/04
摘要: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号:US20180362502A1
公开(公告)日:2018-12-20
申请号:US15988783
申请日:2018-05-24
发明人: Brett Granger , Guoqiang Wang , Ruichao Shen , Jun Ma , Xuechao Xing , Jing He , Yong He , Jiang Long , Bin Wang , Yat Sun Or
IPC分类号: C07D401/14 , C07D417/14 , C07D513/04 , C07D491/08 , C07D487/08
CPC分类号: C07D401/14 , C07D417/14 , C07D487/08 , C07D491/08 , C07D513/04
摘要: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号:US10149835B2
公开(公告)日:2018-12-11
申请号:US15597431
申请日:2017-05-17
发明人: Yat Sun Or , Xuechao Xing , Ruichao Shen , Bin Wang , Brett Granger , Jun Ma , Jing He , Jiang Long , Yong He , Guoqiang Wang
IPC分类号: A61K31/42 , C07D225/04 , C07D213/127 , C07D261/08 , C07C317/38
摘要: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.
-
公开(公告)号:US10080743B2
公开(公告)日:2018-09-25
申请号:US15497359
申请日:2017-04-26
发明人: Yat Sun Or , Bin Wang , Xuechao Xing , Ruichao Shen , Brett Granger , Jun Ma , Jing He , Yong He , Jiang Long , Guoqiang Wang
IPC分类号: C07D261/08 , C07D413/12 , A61K31/42 , A61K31/422
CPC分类号: A61K31/42 , A61K31/422 , C07D261/08 , C07D413/12
摘要: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
-
-
-
-
-
-
-
-